[Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].
作者信息
Wang X Y, Yang R C
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laborator of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):259-264. doi: 10.3760/cma.j.issn.0253-2727.2022.03.014.
Abstract
摘要
相似文献
1
[Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].用于治疗B型血友病的长效重组凝血因子Ⅸ的研究进展
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):259-264. doi: 10.3760/cma.j.issn.0253-2727.2022.03.014.
2
Recombinant clotting factors in the treatment of hemophilia.重组凝血因子在血友病治疗中的应用
Thromb Haemost. 1999 Aug;82(2):516-24.
3
Issues in making a therapeutic choice: recombinant and/or human-derived products.治疗选择中的问题：重组产品和/或人源产品。
Haemophilia. 2001 Jan;7(1):89-90.
4
5
The evolution of recombinant factor replacement for hemophilia.血友病重组因子替代疗法的演变
Transfus Apher Sci. 2019 Oct;58(5):596-600. doi: 10.1016/j.transci.2019.08.010. Epub 2019 Aug 9.
6
Switching haemophilia products and inhibitor risk: a United States' perspective.血友病产品转换与抑制物风险：美国视角
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
7
Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.基于证据的重组FVIIa（诺维乐，尼亚斯塔斯）在儿童和青少年血友病伴抑制剂治疗中的应用。
Transfus Apher Sci. 2008 Feb;38(1):25-32. doi: 10.1016/j.transci.2007.12.002. Epub 2008 Feb 11.
8
Therapeutic properties and safety of recombinant factor VIII and factor IX.重组凝血因子 VIII 和凝血因子 IX 的治疗特性与安全性。
Pol Arch Med Wewn. 2009 Jun;119(6):403-9.
9
Surgery in haemophilic patients with inhibitors.伴有抑制物的血友病患者的手术治疗
Haemophilia. 2004 Sep;10 Suppl 2:1-2. doi: 10.1111/j.1365-2516.2004.00933.x.
10
Sodium content in products used to treat haemophilia.用于治疗血友病的产品中的钠含量。
Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26.
本文引用的文献
1
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.PUPs B-LONG 研究的最终结果：评估 rFIXFc 在既往未治疗的乙型血友病患者中的安全性和疗效。
Blood Adv. 2021 Jul 13;5(13):2732-2739. doi: 10.1182/bloodadvances.2020004085.
2
Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.真实世界中重组凝血因子 IX Fc 融合蛋白（rFIXFc）预防治疗的结果：全国性成人队列的纵向随访。
Haemophilia. 2021 Jul;27(4):618-625. doi: 10.1111/hae.14307. Epub 2021 May 3.
3
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.靶向抗凝血酶治疗 A 型或 B 型血友病的研究性 siRNA 治疗药物 fitusiran-1 期抑制剂队列研究结果。
J Thromb Haemost. 2021 Jun;19(6):1436-1446. doi: 10.1111/jth.15270. Epub 2021 May 18.
4
Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.聚乙二醇化重组人凝血因子IX（N9-GP）治疗B型血友病：关于既往未治疗和低暴露治疗患者安全性和有效性的首次报告
Res Pract Thromb Haemost. 2020 Jul 29;4(7):1101-1113. doi: 10.1002/rth2.12412. eCollection 2020 Oct.
5
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.真实世界数据表明，接受重组凝血因子 IX Fc 融合蛋白（rFIXFc）治疗的乙型血友病患者，在转为 rFIXFc 治疗长达 5 年期间，出血控制得到改善，且可延长给药间隔。
Haemophilia. 2020 Nov;26(6):975-983. doi: 10.1111/hae.14152. Epub 2020 Oct 4.
6
WFH Guidelines for the Management of Hemophilia, 3rd edition.《血友病管理的居家指南》第三版
Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.
7
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.长达 5 年的重组凝血因子 IX Fc 融合蛋白治疗乙型血友病患者的长期安全性和持续疗效：B-YOND 扩展研究结果。
Haemophilia. 2020 Nov;26(6):e262-e271. doi: 10.1111/hae.14036. Epub 2020 Jun 4.
8
The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.澳大利亚切换至使用延长半衰期的因子 VIII 和 IX 的经验集中体现：代表澳大利亚血友病中心主任组织。
Haemophilia. 2020 May;26(3):529-535. doi: 10.1111/hae.13970. Epub 2020 Apr 3.
9
Hemophilia therapy: the future has begun.血友病治疗：未来已来。
Haematologica. 2020 Mar;105(3):545-553. doi: 10.3324/haematol.2019.232132. Epub 2020 Feb 14.
10
[Recent advances in therapies for haemophilia].[血友病治疗的最新进展]
Zhonghua Xue Ye Xue Za Zhi. 2018 Oct 14;39(10):873-876. doi: 10.3760/cma.j.issn.0253-2727.2018.10.018.
Zotero 插件